S 5571 · 119th Congress
Biosimilars Access and Affordability Act
This bill changes when cheaper generic versions of biologic drugs (called biosimilars) become eligible for Medicare price negotiations. Currently, biosimilars can be negotiated immediately once they're approved by the FDA. This bill delays that eligibility by up to 2 years if a biosimilar is expected to enter the ma…
- Sponsor
- Blackburn, Marsha (R-Tennessee)
- Introduced
- 2026-09-28
- Policy area
- Health
Digging through Congress... 🔍